Leadership of the Dan L. Duncan Cancer Center has been fortunate to have an excellent group of internal and external advisors engaged in developing the capabilities of the Center. Based on advice and feedback from the original submission and the advice of our advisors themselves, we have significantly increased the size of our EAB and have brought on individuals who bring a broader range of expertise to provide guidance for the DLDCC. In addition to the EAB, the Center has well developed internal advisory functions including an Executive Committee which reviews and discusses all major decisions and strategic directions and has regular meetings with its Program Leaders and Shared Resource Directors. The Center created a Clinical Research Leadership Committee in 2008 to more effectively ensure that all clinical research conducted within this multi institutional Cancer Center meets the high standards set forth in DLDCC clinical research SOPs and adheres to current federal and state regulations, guidelines, Good Clinical Practices, and BCM Policy. Center and programmatic leadership sponsor retreats, symposium and other activities to effectively plan, communicate and foster scientific interaction. Advice and council, gather from these various groups, as well as intelligence gathered by DLDCC leadership participation in various national and international organizations, is formally reviewed and discussed at annual retreats. This input is then used to inform the development of Strategic Plan that guides decision making and resource allocation on an ongoing basis. Feedback from the formal CCSG review process conducted in 2006 also is incorporated in our plan. The DLDCC Strategic Plan is revised on a regular basis, as goals are completed and new opportunities arise. The Plan was last revised in February 2008, and will be updated as a consequence ofthe CCSG renewal application.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA125123-05
Application #
8296109
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2011-07-01
Budget End
2012-06-30
Support Year
5
Fiscal Year
2011
Total Cost
$22,020
Indirect Cost
Name
Baylor College of Medicine
Department
Type
DUNS #
051113330
City
Houston
State
TX
Country
United States
Zip Code
77030
Boudreaux, Seth P; Duren, Ryan P; Call, Steven G et al. (2018) Drug targeting of NR4A nuclear receptors for treatment of acute myeloid leukemia. Leukemia :
Sukumaran, Sujita; Watanabe, Norihiro; Bajgain, Pradip et al. (2018) Enhancing the Potency and Specificity of Engineered T Cells for Cancer Treatment. Cancer Discov 8:972-987
Kaochar, Salma; Mitsiades, Nicholas (2018) A Novel Mechanism to Drive Castration-Resistant Prostate Cancer. Trends Endocrinol Metab 29:366-368
Johnston, A N; Bu, W; Hein, S et al. (2018) Hyperprolactinemia-inducing antipsychotics increase breast cancer risk by activating JAK-STAT5 in precancerous lesions. Breast Cancer Res 20:42
Ostrom, Quinn T; Kinnersley, Ben; Wrensch, Margaret R et al. (2018) Sex-specific glioma genome-wide association study identifies new risk locus at 3p21.31 in females, and finds sex-differences in risk at 8q24.21. Sci Rep 8:7352
Chen, Fengju; Zhang, Yiqun; Varambally, Sooryanarayana et al. (2018) Molecular Correlates of Metastasis by Systematic Pan-Cancer Analysis Across The Cancer Genome Atlas. Mol Cancer Res :
Morita, Daisuke; Nishio, Nobuhiro; Saito, Shoji et al. (2018) Enhanced Expression of Anti-CD19 Chimeric Antigen Receptor in piggyBac Transposon-Engineered T Cells. Mol Ther Methods Clin Dev 8:131-140
Bajgain, Pradip; Tawinwung, Supannikar; D'Elia, Lindsey et al. (2018) CAR T cell therapy for breast cancer: harnessing the tumor milieu to drive T cell activation. J Immunother Cancer 6:34
Badr, Hoda; Herbert, Krista; Bonnen, Mark D et al. (2018) Dyadic Coping in Patients Undergoing Radiotherapy for Head and Neck Cancer and Their Spouses. Front Psychol 9:1780
Bollard, Catherine M; Tripic, Tamara; Cruz, Conrad Russell et al. (2018) Tumor-Specific T-Cells Engineered to Overcome Tumor Immune Evasion Induce Clinical Responses in Patients With Relapsed Hodgkin Lymphoma. J Clin Oncol 36:1128-1139

Showing the most recent 10 out of 991 publications